Hyaluronate Sodium

Glycosaminoglycan Viscosupplementation agent, Anti-inflammatory

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog Intra-articular 10-20 mg per joint (depending on joint size) Once weekly for 1-3 weeks, or as a single injection Duration: May be repeated every 6-12 months as needed
Notes: Strict aseptic technique required. Some products are approved for IV use in horses, but in dogs, intra-articular is common.
Cat Intra-articular 5-10 mg per joint Once weekly for 1-3 weeks Duration: May be repeated as needed
Notes: Use with caution; cats may be more sensitive to handling.
Horse Intra-articular 20-40 mg per joint (depending on joint size) Once weekly for 1-3 weeks, or as a single injection Duration: May be repeated every 6-12 months
Notes: Also available as IV formulation for equine use; dose for IV is 40 mg once weekly for 3 weeks.
Horse Intravenous 40 mg Once weekly for 3 weeks Duration: May be repeated as needed
Notes: IV formulation is used for general joint disease and may have systemic effects.
Cattle Intra-articular 20-40 mg per joint Once weekly for 1-3 weeks Duration: As needed
Notes: Extra-label use; not FDA-approved for cattle.
Small Ruminants Intra-articular 10-20 mg per joint Once weekly for 1-3 weeks Duration: As needed
Notes: Extra-label use; limited data.
Rabbit Intra-articular 2-5 mg per joint Once weekly for 1-2 weeks Duration: As needed
Notes: Extra-label use; limited data.

Clinical Indications & Species Uses

General Indications
  • Symptomatic treatment of osteoarthritis and joint inflammation
  • Improvement of joint function and mobility
Dog (Canine)
  • Treatment of lameness and joint pain associated with osteoarthritis
  • Adjunct therapy for hip dysplasia
  • Management of acute joint trauma
Cat (Feline)
  • Treatment of osteoarthritis-associated pain and lameness
  • Management of degenerative joint disease
Horse (Equine)
  • Treatment of non-infectious joint inflammation (e.g., osteoarthritis, traumatic arthritis)
  • Viscosupplementation for joint disease
  • Adjunct therapy for navicular syndrome

Pharmacology & Mechanism of Action

Drug Class: Glycosaminoglycan | Pharmacological Group: Viscosupplementation agent, Anti-inflammatory

Mechanism of Action: Hyaluronate sodium is a high-molecular-weight polysaccharide that is a major component of synovial fluid and cartilage. It exerts its effects through several mechanisms: it provides viscoelasticity to synovial fluid, thereby improving joint lubrication and shock absorption; it inhibits the release of inflammatory mediators such as prostaglandins and cytokines; it reduces the activity of matrix metalloproteinases and other degradative enzymes; it scavenges free radicals; and it may stimulate the synthesis of endogenous hyaluronan by synoviocytes. These actions help restore the rheological properties of synovial fluid, reduce pain, and improve joint function.

Pharmacodynamics: Hyaluronate sodium acts locally in the joint after intra-articular injection. It increases the viscosity and elasticity of synovial fluid, which enhances joint lubrication and cushioning. It also has anti-inflammatory effects by reducing the production of inflammatory mediators and inhibiting leukocyte migration and phagocytosis. Additionally, it may promote cartilage repair by stimulating chondrocyte proliferation and proteoglycan synthesis. The clinical effects include reduced pain, improved joint mobility, and decreased lameness in animals with osteoarthritis.

⚑ Pharmacokinetics Summary

Absorption: After intra-articular injection, hyaluronate sodium remains primarily within the joint space. It is not significantly absorbed systemically. The residence time in the joint depends on the molecular weight and formulation; high-molecular-weight products have a longer intra-articular half-life.
Distribution: Within the joint, hyaluronate sodium distributes into the synovial fluid and binds to the surface of cartilage and synovial membrane. It does not penetrate deeply into cartilage or reach significant systemic concentrations.
Metabolism: Hyaluronate sodium is metabolized locally in the joint by hyaluronidases and other enzymes, and also by the liver after systemic absorption (which is minimal). The degradation products are eventually eliminated.
Excretion: The metabolites are excreted primarily via the liver and kidneys. In the joint, the half-life is typically 1-3 days, but the clinical effect may last for weeks to months.
Half-Life: Intra-articular half-life: 1-3 days (depending on molecular weight and formulation); systemic half-life is negligible due to minimal absorption.
Bioavailability: Not applicable for intra-articular administration; systemic bioavailability is negligible.
Protein Binding: Not significantly protein-bound.

Available Formulations & Strengths

Injectable Solution (Intra-articular) 10 mg/mL, 20 mg/mL (Intra-articular)
Injectable Solution (Intravenous) 10 mg/mL (Intravenous)

Contraindications & Clinical Warnings

Contraindications:
  • Known hypersensitivity to hyaluronate or any component
  • Joint infection (septic arthritis) - do not inject into infected joint
  • Intravenous administration in species other than horses (not approved)
  • Do not use in animals with bleeding disorders or on anticoagulant therapy (relative)
Warnings & Clinical Precautions:
  • Use strict aseptic technique to avoid joint infection
  • Do not inject into infected or inflamed joints with suspected sepsis
  • Avoid concurrent use with disinfectants containing quaternary ammonium salts (may precipitate hyaluronate)
  • Use with caution in animals with known hypersensitivity to avian or bacterial proteins (some products are derived from rooster combs or bacterial fermentation)
  • In horses, IV administration should be slow and not mixed with other drugs
  • Safety in pregnant or lactating animals has not been established; use only when clearly needed
  • Do not use in animals with known bleeding disorders

Adverse Effects & Reactions

Common:

  • Transient pain or swelling at injection site
  • Joint effusion
  • Lameness (temporary worsening)

Serious / Severe:

  • Septic arthritis (if aseptic technique is not maintained)
  • Anaphylactic reaction (rare)
  • Joint infection

Rare:

  • Allergic reactions
  • Injection site granuloma
  • Systemic effects (fever, lethargy)

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Corticosteroids (intra-articular) Concurrent use may reduce the efficacy of hyaluronate; corticosteroids may degrade hyaluronate. Avoid simultaneous injection. Moderate
Anticoagulants (e.g., warfarin, heparin) Increased risk of bleeding at injection site; use with caution. Moderate
Nonsteroidal anti-inflammatory drugs (NSAIDs) No significant interaction; may be used concurrently for additive pain relief. Mild
Quaternary ammonium compounds (e.g., benzalkonium chloride) May cause precipitation of hyaluronate; avoid contact. High

Overdose & Toxicity Management

Signs of Toxicity:

  • Joint pain and swelling
  • Lameness
  • Local inflammation
  • Systemic signs (rare): fever, lethargy

Emergency Treatment Protocol: There is no specific antidote. Treatment is symptomatic and supportive. For intra-articular overdose, consider joint aspiration to remove excess fluid. Administer anti-inflammatory drugs (e.g., NSAIDs) if needed. Monitor for signs of infection. In case of anaphylaxis, administer epinephrine and supportive care.

Food Animal Withdrawal Times

πŸ₯© Meat: 0 daysπŸ₯› Milk: 0 daysπŸ₯š Eggs: 0 days

Hyaluronate sodium is not approved for food animals; withdrawal times are not established. In the US, extra-label use in food animals requires a withdrawal period determined by a veterinarian, but due to the local nature of the drug, systemic residues are unlikely. However, for safety, a withdrawal time of at least 0 days is often recommended, but consult regulatory guidelines.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (15-30Β°C / 59-86Β°F). Do not freeze.

Handling & Special Conditions: Protect from light. Keep in original carton until use. Do not use if solution is discolored or contains particulate matter.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for use in horses (IV and IA) and dogs (IA) by the FDA. Some products are also approved for use in cats in certain countries.

Extra-Label (Off-Label) Use: In the US, hyaluronate sodium is approved for use in horses (IV and IA) and dogs (IA). Extra-label use in other species is permitted under AMDUCA (Animal Medicinal Drug Use Clarification Act) with a valid veterinarian-client-patient relationship. For food animals, a withdrawal time must be established by the veterinarian.

Clinical Pearls & Practice Notes

πŸ’‘ Clinical Insights: Hyaluronate sodium is a valuable adjunct in the management of osteoarthritis and joint inflammation in veterinary medicine. It is most commonly used in horses and dogs, with increasing use in cats. Intra-articular injection provides the most direct benefit, but intravenous administration in horses has shown systemic effects. The drug is generally well-tolerated, but strict aseptic technique is essential to prevent joint infection. Clinical response may take several days to weeks, and repeated injections may be necessary. It is often used in combination with NSAIDs, physical therapy, and weight management. In food animals, use is limited due to lack of approval and withdrawal time concerns. Always follow label instructions and consult current veterinary guidelines.

References & Literature

  • πŸ“š Plumb's Veterinary Drug Handbook
  • πŸ“š Papich Veterinary Pharmacology and Therapeutics
  • πŸ“š Compendium of Veterinary Products (CVP)